Moderna and Merck announced a major cancer vaccine breakthrough by August 29, 2026, ending a century of unsuccessful attempts. U.S. regulatory approval could arrive as soon as 2027.
Moderna and Merck announced a breakthrough on August 24, 2026, with their personalised mRNA-based cancer vaccine reducing melanoma recurrence in a large-scale clinical study. This marks the first successful mRNA cancer vaccine in a major trial.
Moderna reported positive results from a melanoma cancer vaccine on 2026-08-20, prompting a stock surge. Experts suggest the personalized vaccine approach could reshape cancer treatment more broadly.
Moderna and Merck announced a successful clinical trial by August 21, 2026, for a personalized mRNA cancer vaccine paired with Merck's immunotherapy drug to treat melanoma. The breakthrough combines a customized vaccine designed to target specific cancer cells with immunotherapy.
Between August 19-21, 2026, US drugmakers Merck and Moderna announced that a personalized mRNA cancer treatment reduced melanoma recurrence in a late-stage trial. The breakthrough builds on mRNA technology from Covid-19 vaccines.
Moderna's stock more than doubled on August 19, 2026 after the company announced positive initial results from a study of its experimental mRNA-based cancer vaccine developed with Merck, which is designed to be tailored to individual patients. The treatment is called intismeran.
Moderna and Merck announced positive Phase 3 trial results for a personalized mRNA-based cancer vaccine combined with immunotherapy in treating melanoma, preventing recurrence and spread of skin cancer. The vaccine, called INTerpath001, showed efficacy in late-stage trials and caused stock prices of both companies to surge on August 19, 2026.
Merck and Moderna announced on August 19, 2026, that their personalized mRNA cancer vaccine intismeran autogene, combined with Merck's immunotherapy Keytruda, significantly reduced melanoma recurrence in late-stage trials. Stock prices for both companies surged on the breakthrough.
Moderna's share price nearly doubled on August 19–20, 2026 following announcement of promising results from a late-stage trial of an experimental, vaccine-based treatment that reduced skin cancer recurrence. Optimism about a potential breakthrough in personalized cancer treatment drove the stock rally.
On August 19–20, 2026, pharmaceutical giants Merck and Moderna announced that an experimental mRNA vaccine treatment demonstrated promise in preventing melanoma recurrence in high-risk patients, sending stock prices soaring. The companies reported positive signals but had not yet published detailed trial data.
Moderna and Merck announced on August 19-21, 2026, that a personalized mRNA cancer vaccine combined with the drug Keytruda significantly reduced the risk of melanoma recurrence and spread in high-risk patients during late-stage trials, marking a major breakthrough in therapeutic cancer vaccines.
Merck and Moderna announced on August 19, 2026, that their mRNA-based melanoma vaccine met its goals in a large clinical trial. The development represents significant progress in cancer immunotherapy and offers potential new treatment options for skin cancer patients.
Moderna and Merck announced on August 19 that their mRNA-based cancer vaccine significantly extended disease-free survival in melanoma patients compared to Keytruda alone in a late-stage trial. Moderna's stock surged 100% following the announcement.